Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

被引：223

作者：

Costa, Aline G. ^{[1
]}

Cusano, Natalie E. ^{[1
]}

Silva, Barbara C. ^{[1
]}

Cremers, Serge ^{[1
]}

Bilezikian, John P. ^{[1
]}

机构：

[1] Columbia Univ, Dis Unit, Div Endocrinol, Coll Phys & Surg,Dept Med, New York, NY 10032 USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2011年 / 7卷 / 08期

关键词：

BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; INHIBITOR ODANACATIB; MOLECULAR-CLONING; BREAST-CANCER; DOUBLE-BLIND; IN-VIVO; PYCNODYSOSTOSIS; COLLAGEN; GENE;

D O I：

10.1038/nrrheum.2011.77

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone remodeling consists of two phases-bone resorption and bone formation-that are normally balanced. When bone resorption exceeds bone formation, pathologic processes, such as osteoporosis, can result. Cathepsin K is a member of the papain family of cysteine proteases that is highly expressed by activated osteoclasts. Cathepsin K readily degrades type I collagen, the major component of the organic bone matrix. With such a major role in the initial process of bone resorption, cathepsin K has become a therapeutic target in osteoporosis. The antiresorptive properties of cathepsin K inhibitors have been studied in phase I and phase II clinical trials. Phase III studies are currently underway for odanacatib, a selective cathepsin K inhibitor.

引用

页码：447 / 456

页数：10

共 50 条

[1] Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
Aline G. Costa
Natalie E. Cusano
Barbara C. Silva
Serge Cremers
John P. Bilezikian
Nature Reviews Rheumatology, 2011, 7 : 447 - 456
[2] Cathepsin K as a target for the treatment of osteoporosis
Smith, WW
Abdel-Meguid, SS
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (06) : 683 - 694
[3] Cathepsin K - a target for the treatment of osteoporosis
Lloyd, A
DRUG DISCOVERY TODAY, 1999, 4 (09) : 441 - 442
[4] Cathepsin K inhibitors: A novel target for osteoporosis therapy
Stoch, S. A.
Wagner, J. A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 172 - 176
[5] Cathepsin K: A therapeutic target for bone diseases
Zhao, Qingxiao
Jia, Yanping
Mao, Yongtao
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 380 (04) : 721 - 723
[6] Cathepsin K is a potential therapeutic target for autoimmune arthritis
Nature Clinical Practice Rheumatology, 2008, 4 (5): : 231 - 231
[7] Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis
Helali, Asadul Mazid
Iti, Farhana Matin
Mohamed, Isa Naina
CURRENT DRUG TARGETS, 2013, 14 (13) : 1591 - 1600
[8] Cathepsin K inhibitors for osteoporosis and potential off-target effects
Bromme, Dieter
Lecaille, Fabien
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (05) : 585 - 600
[9] Cathepsin K - A Novel Molecular Target for Treatment of Osteoporosis: Discovery of Odanacatib
Rodan, Sevgi
BONE, 2010, 46 : S14 - S15
[10] OPG/RANKL: role and therapeutic target in osteoporosis
Marie, P.
Halbout, P.
M S-MEDECINE SCIENCES, 2008, 24 (01): : 105 - 109

← 1 2 3 4 5 →